Mizuho raised the firm’s price target on Gilead (GILD) to $140 from $131 and keeps an Outperform rating on the shares. The firm raised its price target primarily due to: Biktarvy’s loss of exclusivity in the U.S. now expected to be 2036 instead of 2033 post generic lititgation settlements; the total addressable market for PrEP could be much larger than currently appreciated, and; the firm now models roughly 5% growth for Gilead’s HIV business overall, from roughly 3% prior.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences Announces Executive Vice President Departure
- 3 Stocks Flashing ‘Buy Now’ Signals on Technical Charts
- Gilead announces delivery of first lenacapavir shipments to Eswatini, Zambia
- Gilead Sciences: Promising Future in HIV Treatment and Oncology Drives Buy Rating
- Gilead Sciences’ Strategic Advancements in HIV Treatment Bolster Buy Rating and Future Revenue Prospects